Last 12 months
Inside the activity.
0 purchase rows · 145 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 9 |
| Dec 2025 | 0 | 8 |
| Jan 2026 | 0 | 5 |
| Feb 2026 | 0 | 5 |
| Mar 2026 | 0 | 41 |
| Apr 2026 | 0 | 26 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 9 |
| Jul 2026 | 0 | 11 |
| Aug 2026 | 0 | 11 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 18 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 15, 2020 Filed Oct 16, 2020 21:00 UTC |
LO FRANCISChief People Officer
|
Exercise / conversionCommon Stock | 2,000 | $7.80 | $15,600.00 |
DisclosureSEC source: 0001209191-20-055071 · doc4.xml · nonDerivative · entry 1 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2020. Read SEC document |
| October 15, 2020 Filed Oct 16, 2020 21:00 UTC |
HERSHBERG ROBERTDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001209191-20-055072 · doc4.xml · derivative · entry 3 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,000 Underlying: Common Stock · 2,000 shares Expires 2023-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| October 15, 2020 Filed Oct 16, 2020 21:00 UTC |
HERSHBERG ROBERTDirector
|
SaleCommon Stock | 2,000 | $51.51 | $103,020.00 |
DisclosureSEC source: 0001209191-20-055072 · doc4.xml · nonDerivative · entry 2 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $51.00 to $51.99, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| October 15, 2020 Filed Oct 16, 2020 21:00 UTC |
HERSHBERG ROBERTDirector
|
Exercise / conversionCommon Stock | 2,000 | $0.45 | $900.00 |
DisclosureSEC source: 0001209191-20-055072 · doc4.xml · nonDerivative · entry 1 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020. Read SEC document |
| October 14, 2020 Filed Oct 16, 2020 21:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 11,100 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-20-055073 · doc4.xml · derivative · entry 6 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,200 Underlying: Common Stock · 11,100 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| October 14, 2020 Filed Oct 16, 2020 21:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 3,480 | $52.84 | $183,883.20 |
DisclosureSEC source: 0001209191-20-055073 · doc4.xml · nonDerivative · entry 3 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 679 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $52.40 to 53.26, inclusive. Read SEC document |
| October 14, 2020 Filed Oct 16, 2020 21:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 7,620 | $51.87 | $395,249.40 |
DisclosureSEC source: 0001209191-20-055073 · doc4.xml · nonDerivative · entry 2 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,159 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $51.49 to 52.39, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| October 14, 2020 Filed Oct 16, 2020 21:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionCommon Stock | 11,100 | $6.32 | $70,152.00 |
DisclosureSEC source: 0001209191-20-055073 · doc4.xml · nonDerivative · entry 1 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,779 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. Read SEC document |
| October 14, 2020 Filed Oct 16, 2020 21:00 UTC |
GRIFFIN MICHELLE RENEEDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001209191-20-055069 · doc4.xml · derivative · entry 4 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,000 Underlying: Common Stock · 12,000 shares Expires 2029-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 28, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| October 14, 2020 Filed Oct 16, 2020 21:00 UTC |
GRIFFIN MICHELLE RENEEDirector
|
SaleCommon Stock | 7,351 | $53.07 | $390,117.57 |
DisclosureSEC source: 0001209191-20-055069 · doc4.xml · nonDerivative · entry 3 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $52.86 to 53.36, inclusive. Read SEC document |
| October 14, 2020 Filed Oct 16, 2020 21:00 UTC |
GRIFFIN MICHELLE RENEEDirector
|
SaleCommon Stock | 4,649 | $52.48 | $243,979.52 |
DisclosureSEC source: 0001209191-20-055069 · doc4.xml · nonDerivative · entry 2 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,351 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $51.85 to 52.834, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| October 14, 2020 Filed Oct 16, 2020 21:00 UTC |
GRIFFIN MICHELLE RENEEDirector
|
Exercise / conversionCommon Stock | 12,000 | $7.80 | $93,600.00 |
DisclosureSEC source: 0001209191-20-055069 · doc4.xml · nonDerivative · entry 1 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. Read SEC document |
| October 14, 2020 Filed Oct 16, 2020 21:00 UTC |
Pellini Michael JDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-20-055068 · doc4.xml · derivative · entry 4 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 50,000 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2020. F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on February 7, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| October 14, 2020 Filed Oct 16, 2020 21:00 UTC |
Pellini Michael JDirector
|
SaleCommon Stock | 21,745 | $52.95 | $1,151,397.75 |
DisclosureSEC source: 0001209191-20-055068 · doc4.xml · nonDerivative · entry 3 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $52.59 to 53.36, inclusive. Read SEC document |
| October 14, 2020 Filed Oct 16, 2020 21:00 UTC |
Pellini Michael JDirector
|
SaleCommon Stock | 28,255 | $51.89 | $1,466,151.95 |
DisclosureSEC source: 0001209191-20-055068 · doc4.xml · nonDerivative · entry 2 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,745 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $51.49 to 52.435, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| October 14, 2020 Filed Oct 16, 2020 21:00 UTC |
Pellini Michael JDirector
|
Exercise / conversionCommon Stock | 50,000 | $6.55 | $327,500.00 |
DisclosureSEC source: 0001209191-20-055068 · doc4.xml · nonDerivative · entry 1 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2020. Read SEC document |
| October 12, 2020 Filed Oct 15, 2020 01:00 UTC |
LO FRANCISChief People Officer
|
Exercise / conversionStock Option (Right To Buy) · Derivative | 25,000 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001209191-20-054848 · doc4.xml · derivative · entry 4 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,000 Underlying: Common Stock · 25,000 shares Expires 2029-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2020. F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on May 6, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| October 12, 2020 Filed Oct 15, 2020 01:00 UTC |
LO FRANCISChief People Officer
|
SaleCommon Stock | 25,000 | $52.80 | $1,320,000.00 |
DisclosureSEC source: 0001209191-20-054848 · doc4.xml · nonDerivative · entry 2 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2020. Read SEC document |
| October 12, 2020 Filed Oct 15, 2020 01:00 UTC |
LO FRANCISChief People Officer
|
Exercise / conversionCommon Stock | 25,000 | $7.80 | $195,000.00 |
DisclosureSEC source: 0001209191-20-054848 · doc4.xml · nonDerivative · entry 1 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2020. Read SEC document |
| October 08, 2020 Filed Oct 8, 2020 23:26 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 24,260 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001209191-20-054352 · doc4.xml · derivative · entry 12 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,600 Underlying: Common Stock · 24,260 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F8 · derivative.exercise_date: The options are fully vested and exercisable. Read SEC document |
| October 08, 2020 Filed Oct 8, 2020 23:26 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 1,400 | $51.37 | $71,918.00 |
DisclosureSEC source: 0001209191-20-054352 · doc4.xml · nonDerivative · entry 9 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,778,180 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F7 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $51.28 to 51.42, inclusive. Read SEC document |
| October 08, 2020 Filed Oct 8, 2020 23:26 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 22,860 | $50.56 | $1,155,801.60 |
DisclosureSEC source: 0001209191-20-054352 · doc4.xml · nonDerivative · entry 8 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,779,580 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F6 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $50.08 to 51.00, inclusive. Read SEC document |
| October 08, 2020 Filed Oct 8, 2020 23:26 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
Exercise / conversionCommon Stock | 24,260 | $0.33 | $8,005.80 |
DisclosureSEC source: 0001209191-20-054352 · doc4.xml · nonDerivative · entry 7 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,802,440 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. Read SEC document |
| October 08, 2020 Filed Oct 8, 2020 23:24 UTC |
Cohen Chad MChief Financial Officer
|
Exercise / conversionStock Option (Right To Buy) · Derivative | 30,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-20-054351 · doc4.xml · derivative · entry 4 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550,000 Underlying: Common Stock · 30,000 shares Expires 2025-08-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| October 08, 2020 Filed Oct 8, 2020 23:24 UTC |
Cohen Chad MChief Financial Officer
|
SaleCommon Stock | 6,254 | $51.36 | $321,205.44 |
DisclosureSEC source: 0001209191-20-054351 · doc4.xml · nonDerivative · entry 3 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $51.10 to 51.55, inclusive. Read SEC document |
| October 08, 2020 Filed Oct 8, 2020 23:24 UTC |
Cohen Chad MChief Financial Officer
|
SaleCommon Stock | 23,746 | $50.46 | $1,198,223.16 |
DisclosureSEC source: 0001209191-20-054351 · doc4.xml · nonDerivative · entry 2 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,254 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $50.05 to 50.98, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| October 08, 2020 Filed Oct 8, 2020 23:24 UTC |
Cohen Chad MChief Financial Officer
|
Exercise / conversionCommon Stock | 30,000 | $6.32 | $189,600.00 |
DisclosureSEC source: 0001209191-20-054351 · doc4.xml · nonDerivative · entry 1 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019. Read SEC document |
| October 07, 2020 Filed Oct 8, 2020 23:26 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001209191-20-054352 · doc4.xml · derivative · entry 11 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,860 Underlying: Common Stock · 50,000 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F8 · derivative.exercise_date: The options are fully vested and exercisable. Read SEC document |
| October 07, 2020 Filed Oct 8, 2020 23:26 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 48,800 | $50.20 | $2,449,760.00 |
DisclosureSEC source: 0001209191-20-054352 · doc4.xml · nonDerivative · entry 6 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,778,180 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F5 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $49.74 to 50.71, inclusive. Read SEC document |
| October 07, 2020 Filed Oct 8, 2020 23:26 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 1,200 | $49.40 | $59,280.00 |
DisclosureSEC source: 0001209191-20-054352 · doc4.xml · nonDerivative · entry 5 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,826,980 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $48.97 to 49.70, inclusive. Read SEC document |
| October 07, 2020 Filed Oct 8, 2020 23:26 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
Exercise / conversionCommon Stock | 50,000 | $0.33 | $16,500.00 |
DisclosureSEC source: 0001209191-20-054352 · doc4.xml · nonDerivative · entry 4 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,828,180 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. Read SEC document |
| October 06, 2020 Filed Oct 7, 2020 23:00 UTC |
BALDO LANCEChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 6,250 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001209191-20-054221 · doc4.xml · derivative · entry 4 BALDO LANCE · CIK 0001780773 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 393,750 Underlying: Common Stock · 6,250 shares Expires 2029-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2020. F4 · derivative.exercise_date: The options vested with respect to 1/4 of the shares on May 6, 2020, with 1/48 of the shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| October 06, 2020 Filed Oct 7, 2020 23:00 UTC |
BALDO LANCEChief Medical Officer
|
SaleCommon Stock | 2,014 | $49.84 | $100,377.76 |
DisclosureSEC source: 0001209191-20-054221 · doc4.xml · nonDerivative · entry 3 BALDO LANCE · CIK 0001780773 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $49.47 to 50.065, inclusive. Read SEC document |
| October 06, 2020 Filed Oct 7, 2020 23:00 UTC |
BALDO LANCEChief Medical Officer
|
SaleCommon Stock | 4,236 | $48.90 | $207,140.40 |
DisclosureSEC source: 0001209191-20-054221 · doc4.xml · nonDerivative · entry 2 BALDO LANCE · CIK 0001780773 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,014 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $48.44 to 49.39, inclusive. Read SEC document |
| October 06, 2020 Filed Oct 7, 2020 23:00 UTC |
BALDO LANCEChief Medical Officer
|
Exercise / conversionCommon Stock | 6,250 | $7.80 | $48,750.00 |
DisclosureSEC source: 0001209191-20-054221 · doc4.xml · nonDerivative · entry 1 BALDO LANCE · CIK 0001780773 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2020. Read SEC document |
| October 06, 2020 Filed Oct 8, 2020 23:26 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 18,280 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001209191-20-054352 · doc4.xml · derivative · entry 10 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,860 Underlying: Common Stock · 18,280 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F8 · derivative.exercise_date: The options are fully vested and exercisable. Read SEC document |
| October 06, 2020 Filed Oct 8, 2020 23:26 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 8,102 | $49.83 | $403,722.66 |
DisclosureSEC source: 0001209191-20-054352 · doc4.xml · nonDerivative · entry 3 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,778,180 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $49.41 to 50.31, inclusive. Read SEC document |
| October 06, 2020 Filed Oct 8, 2020 23:26 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 10,178 | $48.99 | $498,620.22 |
DisclosureSEC source: 0001209191-20-054352 · doc4.xml · nonDerivative · entry 2 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,786,282 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $48.53 to 49.40, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| October 06, 2020 Filed Oct 8, 2020 23:26 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
Exercise / conversionCommon Stock | 18,280 | $0.33 | $6,032.40 |
DisclosureSEC source: 0001209191-20-054352 · doc4.xml · nonDerivative · entry 1 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,796,460 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. Read SEC document |
| October 01, 2020 Filed Oct 2, 2020 00:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 600 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001209191-20-052782 · doc4.xml · derivative · entry 6 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,140 Underlying: Common Stock · 600 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F4 · derivative.exercise_date: The options are fully vested and exercisable. Read SEC document |
| October 01, 2020 Filed Oct 2, 2020 00:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 600 | $50.05 | $30,030.00 |
DisclosureSEC source: 0001209191-20-052782 · doc4.xml · nonDerivative · entry 4 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,778,180 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $50.01 to 50.12, inclusive. Read SEC document |
| October 01, 2020 Filed Oct 2, 2020 00:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
Exercise / conversionCommon Stock | 600 | $0.33 | $198.00 |
DisclosureSEC source: 0001209191-20-052782 · doc4.xml · nonDerivative · entry 3 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,778,780 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. Read SEC document |
| October 01, 2020 Filed Oct 2, 2020 00:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 14,725 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001209191-20-052783 · doc4.xml · derivative · entry 6 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,725 shares Expires 2024-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2019. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| October 01, 2020 Filed Oct 2, 2020 00:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 14,725 | $49.00 | $721,525.00 |
DisclosureSEC source: 0001209191-20-052783 · doc4.xml · nonDerivative · entry 4 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2019. Read SEC document |
| October 01, 2020 Filed Oct 2, 2020 00:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionCommon Stock | 14,725 | $0.84 | $12,369.00 |
DisclosureSEC source: 0001209191-20-052783 · doc4.xml · nonDerivative · entry 3 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,725 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2019. Read SEC document |
| October 01, 2020 Filed Oct 2, 2020 23:00 UTC |
BENZENO SHARONChief Business Development Off
|
Exercise / conversionCommon Stock (Right to Buy) · Derivative | 1,562 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0001209191-20-053371 · doc4.xml · derivative · entry 8 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,188 Underlying: Common Stock · 1,562 shares Expires 2029-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. F6 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on January 1, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| October 01, 2020 Filed Oct 2, 2020 23:00 UTC |
BENZENO SHARONChief Business Development Off
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,605 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-20-053371 · doc4.xml · derivative · entry 7 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 2,605 shares Expires 2028-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on October 1, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| October 01, 2020 Filed Oct 2, 2020 23:00 UTC |
BENZENO SHARONChief Business Development Off
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,604 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-20-053371 · doc4.xml · derivative · entry 6 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,855 Underlying: Common Stock · 2,604 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| October 01, 2020 Filed Oct 2, 2020 23:00 UTC |
BENZENO SHARONChief Business Development Off
|
SaleCommon Stock | 893 | $49.26 | $43,989.18 |
DisclosureSEC source: 0001209191-20-053371 · doc4.xml · nonDerivative · entry 5 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $49.15 to 49.34, inclusive. Read SEC document |
| October 01, 2020 Filed Oct 2, 2020 23:00 UTC |
BENZENO SHARONChief Business Development Off
|
SaleCommon Stock | 5,878 | $48.46 | $284,847.88 |
DisclosureSEC source: 0001209191-20-053371 · doc4.xml · nonDerivative · entry 4 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 893 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $48.12 to 49.00, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.